Recognizing the community’s concern about the USPSTF recommendation regarding screening for ovarian cancer in September 2012, OCRF responded by writing a New York Times Letter to the Editor to reinforce the fact that research is the key and expand our message to a much wider audience. It was published on September 21, 2012.
Related Topics
FDA Approves Lifyorli Plus Abraxane for Platinum-Resistant Ovarian Cancer
On March 25, 2026, the FDA approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA approval of Keytruda (pembrolizumab) with … Continued
The Overview: March 2026
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
April Programs: New Offerings, Fresh Topics, and More
April is a full month at OCRA, with several new programs joining our ongoing lineup of workshops, educational sessions, and community events. Whether you’re looking for practical guidance, clinical information, or simply a chance to connect and create, there’s something here for you. New and Expanded Programs Advanced Care Planning Workshop Series April 6, 13, … Continued